Literature DB >> 9881510

Antibiotic properties of bovine lactoferrin on Helicobacter pylori.

E J Dial1, L R Hall, H Serna, J J Romero, J G Fox, L M Lichtenberger.   

Abstract

To investigate a potential new treatment for gastric Helicobacter pylori infection, we have examined the use of the natural antibiotic lactoferrin, found in bovine milk, for activity against Helicobacter species both in vitro and in vivo. Lactoferrin was bacteriostatic to H. pylori when cultured at concentrations > or =0.5 mg/ml. Growth of H. pylori was not inhibited by another milk constituent, lysozyme, or by a metabolite of lactoferrin, lactoferricin B, but growth was inhibited by the iron chelator deferoxamine mesylate. Lactoferrin inhibition of growth could be reversed by addition of excess iron to the medium. Lactoferrin in retail dairy milk was found to be more stable intragastrically than unbuffered, purified lactoferrin. Treatment of H. felis-infected mice with lactoferrin partially reversed mucosal disease manifestations. It is concluded that bovine lactoferrin has significant antimicrobial activity against Helicobacter species in vitro and in vivo. Bovine lactoferrin should be further investigated for possible use in H. pylori infections in man.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881510     DOI: 10.1023/a:1026675916421

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  Biological role of lactoferrin.

Authors:  L Sánchez; M Calvo; J H Brock
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

Review 2.  A review: the active peptide of lactoferrin.

Authors:  M Tomita; M Takase; W Bellamy; S Shimamura
Journal:  Acta Paediatr Jpn       Date:  1994-10

Review 3.  Lactoferrin: a general review.

Authors:  P F Levay; M Viljoen
Journal:  Haematologica       Date:  1995 May-Jun       Impact factor: 9.941

4.  Direct activity of recombinant human lactoferrin against Helicobacter pylori.

Authors:  S Miehlke; R Reddy; M S Osato; P P Ward; O M Conneely; D Y Graham
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

5.  Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis.

Authors:  A B Thompson; T Bohling; F Payvandi; S I Rennard
Journal:  J Lab Clin Med       Date:  1990-02

6.  Expression of lactoferrin in human stomach.

Authors:  Y A Luqmani; T A Campbell; C Bennett; R C Coombes; I M Paterson
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

7.  Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice.

Authors:  J G Fox; X Li; R J Cahill; K Andrutis; A K Rustgi; R Odze; T C Wang
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

Review 8.  Bovine mammary lactoferrin: implications from messenger ribonucleic acid (mRNA) sequence and regulation contrary to other milk proteins.

Authors:  F L Schanbacher; R E Goodman; R S Talhouk
Journal:  J Dairy Sci       Date:  1993-12       Impact factor: 4.034

9.  Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis.

Authors:  S L Hazell; T J Borody; A Gal; A Lee
Journal:  Am J Gastroenterol       Date:  1987-04       Impact factor: 10.864

10.  Iron acquisition by Helicobacter pylori: importance of human lactoferrin.

Authors:  M O Husson; D Legrand; G Spik; H Leclerc
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

View more
  13 in total

1.  Does bovine lactoferrin inhibit Helicobacter pylori?

Authors:  C Joshi; N Wattanapenpaiboon; M L Wahlqvist; P Midolo; J Lambert
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  Human lactoferrin increases Helicobacter pylori internalisation into AGS cells.

Authors:  Dorien S Coray; Jack A Heinemann; Peter C Tyrer; Jacqueline I Keenan
Journal:  World J Microbiol Biotechnol       Date:  2012-02-07       Impact factor: 3.312

3.  Influence of age and duration of infection on bacterial load and immune responses to Helicobacter pylori infection in a murine model.

Authors:  T Minoura; S Kato; S Otsu; M Kodama; T Fujioka; K Iinuma; A Nishizono
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

4.  N-acetylcysteine, a novel treatment for Helicobacter pylori infection.

Authors:  Hien Quoc Huynh; Richard T L Couper; Cuong D Tran; Lynette Moore; Richard Kelso; Ross N Butler
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

5.  Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial.

Authors:  Caroline Maria den Hoed; A C de Vries; P B F Mensink; C M Dierikx; H Suzuki; L Capelle; H van Dekken; R Ouwendijk; E J Kuipers
Journal:  Can J Gastroenterol       Date:  2011-04       Impact factor: 3.522

Review 6.  Clinical research review: usefulness of bovine lactoferrin in child health.

Authors:  Momoko Miyakawa; Hirotsugu Oda; Miyuki Tanaka
Journal:  Biometals       Date:  2022-08-09       Impact factor: 3.378

7.  Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemic immunization using bacterial antigen-aluminium hydroxide.

Authors:  T Minoura; S Kato; S Otsu; T Fujioka; K Iinuma; A Nishizono
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 8.  Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: a review.

Authors:  Aarti Sachdeva; Swapnil Rawat; Jitender Nagpal
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

9.  Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice.

Authors:  Betty P Guo; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial.

Authors:  Fahmy H Hablass; Sameh A Lashen; Eman A Alsayed
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.